| Revenue growth | 19% YoY for Q2 FY27 |
|---|---|
| Margins | Gross margin steady at ~32%; EBITDA margin at ~12.5% |
| Demand visibility | Healthy momentum in domestic business; export recovery |
| Management confidence | High; citing scale benefits and R&D capabilities |
Growth
Revenue grew 19% YoY to Rs. 697.6 Cr; PAT grew 5.4% YoY to Rs. 38.9 Cr. Export sales surged 33.8% YoY.
Outlook
Approved KSA greenfield facility; 5,000 MTPA Thailand facility commissioned. Focused on high-margin segments like Pharma and Oil & Gas.
Risks
Raw material volatility, geopolitical uncertainty, and cautious customer behavior. Higher depreciation from long-term projects impacted PAT.
Investor Presentation filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹410.80
- Market cap
- ₹2,276 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 14.9×Sector 34.5×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth